This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mindfulness-Based Art Therapy for Cancer Patients

This study has been completed.
Information provided by:
National Center for Complementary and Integrative Health (NCCIH) Identifier:
First received: May 2, 2002
Last updated: August 17, 2006
Last verified: July 2006
The purpose of this study is to determine whether cancer patients who receive the mindfulness-based art therapy (MBAT) program demonstrate improvement in health-related quality of life, a reduction in stress-related symptoms, and enhanced coping responses.

Condition Intervention
Cancer Behavioral: Mindfulness-based at therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Educational/Counseling/Training
Official Title: Mindfulness-Based Art Therapy for Cancer Patients

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):

Estimated Enrollment: 114
Study Start Date: April 2002
Estimated Study Completion Date: December 2003
Detailed Description:
Psychosocial interventions, especially supportive-expressive group therapies, have been associated with significant improvements in health status, quality of life and coping behaviors, in patients with cancer. The purpose of the proposed pilot research study is to investigate a newly developed group therapy for cancer patients, MBAT. This proposed, randomized, controlled study follows a successful preliminary investigation of MBAT conducted at Thomas Jefferson University Hospital. MBAT integrates known benefits of art therapy, group therapy, and mindfulness-based stress reduction. Each of these fundamentally different modalities has documented usefulness in the treatment of cancer patients. The multi-modal approach is designed to enhance both the supportive and expressive aspects of the group experience. The study will be done with 96 patients who have a variety of cancer types. Participants will be matched for age and assigned randomly to either the MBAT experimental group or a non-intervention control group. Both groups will continue to receive their usual oncologic/medical care. The MBAT program consists of eight weekly meetings of two and one half-hours in length. At the end of the eight weeks, participants in the control group will be crossed over to the experimental intervention arm for an additional eight weeks. Participants will be assessed pre- and post-intervention on measures of health-related quality of life, psychological distress, and coping, using standardized outcome instruments (SF-36, SCL-90-R and COPE). Our long-term goal is to collect sufficient data to determine the overall efficacy of this promising intervention and to identify which patients are particularly likely to benefit from MBAT.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of cancer or cancer recurrence within the past 2 years.
  • Able to tolerate 8 weekly groups, 2 1/2 hours in length


  • Less than 4 months from original or recurrent diagnosis or beyond 2 years
  • Physically unable to attend groups
  • Non-stabilized major mental disorder
  • Children
  • Comprehension of written and spoken English at a level of less than 4th grade.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00034970

United States, Pennsylvania
Thomas Jefferson University Hospital/Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: Daniel A. Monti, MD Thomas Jefferson University
Study Director: Caroline Peterson, MA Thomas Jefferson University
  More Information

Publications: Identifier: NCT00034970     History of Changes
Other Study ID Numbers: R21AT000683-01 ( U.S. NIH Grant/Contract )
Study First Received: May 2, 2002
Last Updated: August 17, 2006

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
alternative medicine
combination cancer therapy
group therapy
human therapy evaluation
neoplasm /cancer chemotherapy
gender difference
outcomes research
psychological aspect of cancer
psychological stressor
quality of life
racial /ethnic difference
stress management
behavioral /social science research
patient oriented research processed this record on August 18, 2017